Login to Your Account

Clinic Roundup

Friday, August 31, 2012
• Transition Therapeutics Inc., of Toronto, reported that its licensing partner, Elan Corp. plc, of Dublin, Ireland, has commenced a Phase II trial of oral ELND005 (scyllo-inositol) as an adjunctive maintenance treatment in patients with bipolar I disorder to delay the time to occurrence of mood episodes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription